This article is more than 5 years old. Information may no longer be current.

Lucentis approved in Japan for treating wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BASEL, Switzerland — Health authorities in Japan have approved ranibizumab for treating subfoveal wet age-related macular degeneration, according to a press release from Novartis, the co-developer of the drug.

This follows results from a clinical study in Japan that showed that Lucentis (ranibizumab, Genentech/Novartis) significantly improved vision in patients compared with baseline, the release said.

Novartis owns exclusive commercialization rights for the drug outside the United States.